To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

August 23, 2015

Impact Since 2002

The EndBrainCancer Initiative has been born out of the work of the Chris Elliott Fund. Founded in 2002, Chris Elliott Fund has worked vigorously and extensively helping thousands of patients and their families.

Effecting Change

From the day it was founded in 2002, the EndBrainCancer Initiative | Chris Elliott Fund has been dedicated to changing how brain cancer is treated and to offering HOPE to brain cancer patients and their families while advancing science.

  • 2002-2007: provided the seed research money that led to the discovery that Glioblastoma Multiforme (GBM) is not 1 disease but a subclass of 2 diseases.
  • Funded research that identified and prioritized the genes that cause GBM which inspired a multi-center effort across the U.S. to determine the alterations in all human cancers.
  • Advocated on issues of national public health policy including FDA approval for new treatment devices, reimbursement for new treatment options and proper coding.
  • 2015: launched the EndBrainCancer Initiative, a nation-wide collaborative of industry leaders, research scientists and leading physicians to change the clinical trial process and focus on immunotherapy, vaccines, Phase 0 clinical trials and personalized medicine.

A Growing Need for our Services Nationally

Fueled by CEF’s enhanced national online presence, Patient Support Services & Call Center, growing reputation, and strategic partnerships, demand for our services has grown tenfold to 7200+ inquiries per month. As we shift from the Chris Elliott Fund to the EndBrain-Cancer Initiative and grow capacity, we expect to expand and serve 4800 patients/families annually. The program will serve adult and pediatric patients.

A slide show detailing the strategy and priorities of the End Brain Cancer Initiative is available in PDF format.


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram